ONO Pharmaceutical Co Ltd is a Japanese pharmaceutical company that operates in the specialty pharma sector. The company was founded in 1717 and has since grown to become one of the leading pharmaceutical companies in Japan. ONO Pharmaceutical Co Ltd is committed to sustainability and has taken significant steps towards decarbonisation, corporate energy, corporate PPA, and renewable energy.

Decarbonisation is a critical issue that ONO Pharmaceutical Co Ltd takes seriously. The company has set a goal to reduce its greenhouse gas emissions by 30% by 2030. To achieve this goal, ONO Pharmaceutical Co Ltd has implemented various measures, including energy-saving initiatives, the use of renewable energy, and the adoption of low-carbon technologies. The company has also established an Environmental Management System (EMS) to manage its environmental impact and ensure compliance with environmental regulations.

Corporate energy is another area of focus for ONO Pharmaceutical Co Ltd. The company has implemented various measures to reduce its energy consumption, including the installation of energy-efficient lighting and equipment. ONO Pharmaceutical Co Ltd has also implemented a company-wide energy-saving campaign to raise awareness among employees and encourage them to adopt energy-saving practices. The company has also established an Energy Management System (EnMS) to monitor and manage its energy consumption.

Corporate Power Purchase Agreements (PPAs) are an essential tool for companies looking to transition to renewable energy. ONO Pharmaceutical Co Ltd has signed several corporate PPAs to purchase renewable energy from wind and solar power plants. The company has also invested in renewable energy projects, including a solar power plant in Japan. These investments in renewable energy have not only helped ONO Pharmaceutical Co Ltd reduce its carbon footprint but have also provided the company with a stable and cost-effective source of energy.

Renewable energy is a key focus area for ONO Pharmaceutical Co Ltd. The company has set a goal to increase its use of renewable energy to 50% by 2030. To achieve this goal, ONO Pharmaceutical Co Ltd has invested in renewable energy projects and signed corporate PPAs to purchase renewable energy. The company has also implemented various measures to promote the use of renewable energy, including the installation of solar panels on its facilities.

In addition to its commitment to sustainability, ONO Pharmaceutical Co Ltd is also focused on innovation and research. The company has a strong pipeline of products in development, including treatments for cancer, autoimmune diseases, and infectious diseases. ONO Pharmaceutical Co Ltd also collaborates with other companies and research institutions to develop new treatments and technologies.

ONO Pharmaceutical Co Ltd has a strong corporate culture that emphasizes integrity, respect, and teamwork. The company values diversity and inclusion and has implemented various initiatives to promote these values. ONO Pharmaceutical Co Ltd also has a strong commitment to corporate social responsibility and has implemented various initiatives to support the communities in which it operates.

In conclusion, ONO Pharmaceutical Co Ltd is a leading pharmaceutical company in Japan that is committed to sustainability and innovation. The company has taken significant steps towards decarbonisation, corporate energy, corporate PPA, and renewable energy. ONO Pharmaceutical Co Ltd's commitment to sustainability is reflected in its environmental management system, energy management system, and investment in renewable energy projects. The company's strong corporate culture and commitment to corporate social responsibility make it a leader in the pharmaceutical industry.